一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:FOXP3: A Player of Immunogenetic Architecture in Lung Cancer.
FOXP3: A Player of Immunogenetic Architecture in Lung Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
转录因子叉头框蛋白3(FOXP3)被认为是免疫系统中表达于调节性T细胞(Tregs)的重要组分。Tregs是调节免疫稳态和自身耐受的免疫抑制细胞。FOXP3最初被认为是Tregs特异性分子,但近期研究指出FOXP3在多种良性肿瘤和癌中均有表达。绝大多数数据显示FOXP3与不良预后相关,尽管也有少数报道提示该分子具有相反的功能。在此,我们综述了FOXP3在肺癌免疫遗传学架构中作用的最新研究进展,肺癌是癌症相关死亡的首要原因。我们讨论了肿瘤FOXP3表达的预后意义、肿瘤浸润FOXP3淋巴细胞、肿瘤微环境中的肿瘤FOXP3以及FOXP3靶向治疗的潜力。
The transcription factor forkhead box protein 3 (FOXP3) is considered to be a prominent component of the immune system expressed in regulatory T cells (Tregs). Tregs are immunosuppressive cells that regulate immune homeostasis and self-tolerance.
FOXP3 was originally thought to be a Tregs-specific molecule, but recent studies have pinpointed that FOXP3 is expressed in a diversity of benign tumors and carcinomas. The vast majority of the data have shown that FOXP3 is correlated with an unfavorable prognosis, although there are some reports indicating the opposite function of this molecule.
Here, we review recent progress in understanding the FOXP3 role in the immunogenetic architecture of lung cancer, which is the leading cause of cancer-related death.
We discuss the prognostic significance of tumor FOXP3 expression, tumor-infiltrating FOXP3-lymphocytes, tumor FOXP3 in tumor microenvironments and the potential of FOXP3-targeted therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。